Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-15
2011-03-15
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S276000, C544S277000
Reexamination Certificate
active
07906518
ABSTRACT:
The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2′,3′-methylidene acetal adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to compounds that are pro-drugs of adenosine receptor agonists, and to their use as therapeutic compounds, in particular as analgesic or anti-inflammatory compounds, or as disease modifying antirheumatic drugs (DMARDs), and to methods of preventing, treating or ameliorating pain or inflammation using these compounds.
REFERENCES:
patent: 6117878 (2000-09-01), Linden
patent: 6894021 (2005-05-01), Belardinelli et al.
patent: 7553823 (2009-06-01), Zablocki et al.
patent: 2002/0147174 (2002-10-01), Jones et al.
patent: 2003/0040502 (2003-02-01), Salzman et al.
patent: 2004/0180948 (2004-09-01), Linden et al.
patent: 2004/0266722 (2004-12-01), Devos et al.
patent: 2005/0059683 (2005-03-01), Zablocki et al.
patent: 2005/0159388 (2005-07-01), Plourde et al.
patent: 2005/0261236 (2005-11-01), Okusa et al.
patent: 2007/0093446 (2007-04-01), Douglass et al.
patent: 2007/0123544 (2007-05-01), Plourde et al.
patent: 2007/0208040 (2007-09-01), Elzein et al.
patent: 2007/0219221 (2007-09-01), Zeng et al.
patent: 2007/0232626 (2007-10-01), Jacobson et al.
patent: 2007/0274910 (2007-11-01), Wilson et al.
patent: 2007/0299089 (2007-12-01), Belardinelli et al.
patent: 2008/0027022 (2008-01-01), Linden et al.
patent: 2008/0176858 (2008-07-01), Beauglehole et al.
patent: 2008/0214581 (2008-09-01), Allen et al.
patent: 2008/0242673 (2008-10-01), Moorman
patent: 2008/0262001 (2008-10-01), Kranenburg et al.
patent: 2008/0312160 (2008-12-01), Guerrant et al.
patent: 2009/0012035 (2009-01-01), Jacobson et al.
patent: 2009/0054476 (2009-02-01), Goblyos et al.
patent: 2009/0081764 (2009-03-01), Pausch et al.
patent: 2009/0099212 (2009-04-01), Zablocki et al.
patent: 2009/0123510 (2009-05-01), Cronstein et al.
patent: 2009/0156544 (2009-06-01), Elzein et al.
patent: 2009/0170805 (2009-07-01), Tan et al.
patent: 2009/0181920 (2009-07-01), Watkins et al.
patent: 2009/0203689 (2009-08-01), Dhalla et al.
patent: 2009/0247745 (2009-10-01), Aranyi et al.
patent: 2009/0325967 (2009-12-01), Fairhurst et al.
patent: 0997473 (2000-05-01), None
patent: 1491201 (2004-12-01), None
patent: WO-2004052377 (2004-06-01), None
patent: WO-2004078183 (2004-09-01), None
patent: WO-2004078184 (2004-09-01), None
patent: WO-2005084653 (2005-09-01), None
Keeling, Suzanne E. et al., “The Discovery and Synthesis of Highly Potent, A2a Receptor Agonists,” Bioorganic & Medicinal Chemistry Letters 2000, vol. 10, p. 403-406.
Doytchinova, I. et al., “Adenosine A2A receptor agonists: CoMFA-based selection of the most predictive conformation,” SAR and QSAR in Environmental Research 2002, vol. 13, No. 2, p. 227-235.
Berch Mark L
CBT Development Limited
Edwards Angell Palmer & & Dodge LLP
Hai Jeffrey D.
Yang Weiying
LandOfFree
Therapeutic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2682954